SCHEMBL2374430

SCHEMBL2374430

CCOC(=O)C(Cc1ncccn1)N(Cc1ccc(-c2ccncc2)cc1)C(=O)/C=C/c1ccc(C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 4/20 0.39
NOS1 P29475 4/20 0.39
NOS2 P35228 4/20 0.39
CYP1A1 P04798 2/20 0.39
CYP1B1 Q16678 2/20 0.39
MAOB P27338 2/20 0.39
PPARD Q03181 2/20 0.38
PPARA Q07869 2/20 0.38
PPARG P37231 1/20 0.38
PPID Q08752 1/20 0.37
HTR5A P47898 2/20 0.37
MAOA P21397 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.35
MMP1 P03956 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
HTR1D P28221 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374435 1.00 NOS3 (0.39) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2373585 0.88 HTR5A (0.39) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2373580 0.88 HTR5A (0.39) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2376075 0.86 NOS3 (0.37) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2376078 0.86 NOS3 (0.37) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2375181 0.80 NOS3 (0.46) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2375182 0.80 NOS3 (0.46) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2375187 0.80 NOS3 (0.46) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2375206 0.79 NOS3 (0.46) NOS3NOS1NOS2CYP1A1CYP1B1
SCHEMBL2375200 0.79 NOS3 (0.46) NOS3NOS1NOS2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 NOS3 783/4885NOS1 996/4885NOS2 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.